The mammalian target of rapamycin (mTOR) controls cell proliferation, growth, differentiation, motility and survival. Transformed or tumor cells with dysregulated mTOR signaling have shown higher susceptibility to inhibitors of mTOR than normal cells, suggesting mTOR inhibitors as potential tumor-selective therapeutic agents. Clinical trials have demonstrated that rapamycin and its derivatives, CCI-779, RAD001 and AP23573 (designated rapamycins) are promising anticancer drugs. They specifically block the function of mTOR, inhibiting growth of types of solid tumors with only mild side effects in patients. However, the anticancer mechanism of rapamycins remains obscure. While intense studies have focused on the role of mTOR in controlling cell proliferation and growth, little is known about how mTOR regulates cell motility. Preliminary studies show that rapamycin inhibits insulin-like growth factor-l (IGF-I) or 10% fetal bovine serum-stimulated motility of a panel of tumor cell lines in culture, suggesting a pivotal role of mTOR not only in cell proliferation but also in cell motility. The long-term goal of the applicant is to understand the molecular mechanism of IGF-l-mTOR signaling in tumorigenesis and metastasis, providing data for development of tumor-selective therapy. Because dysregulation of IGF-l-mTOR signaling pathway occurs frequently in human tumors, the proposed studies will focus on elucidating how mTOR regulates IGF-l-induced cell motility. With a combination of biochemical, molecular, cellular and genetic approaches, the specific aims of this proposal are to determine: (1) whether rapamycin inhibition of cell motility is a consequence of inhibition of mTOR kinase activity, and results from inhibition of signaling to S6K1 and/or 4E-BP1 established pathways downstream of mTOR, or through a novel pathway signaling through protein phosphatase 2A (PP2A) or other S/T phosphatases (PP4, PP5 and PP6); (2) how inhibition of mTOR by rapamycin prevents IGF-I- stimulated phosphorylation of focal adhesion proteins, including focal adhesion kinase (FAK), p130Cas and paxillin. Data generated from this work will not only provide invaluable insights into the mTOR-mediated signaling pathways, but also make significant contributions to the molecular understanding of tumor cell motility, which is crucial for development of metastasis. The findings may lead to design of novel drugs for the treatment and prevention of metastases. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA115414-01A1
Application #
7139382
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Woodhouse, Elizabeth
Project Start
2006-08-08
Project End
2010-07-30
Budget Start
2006-08-08
Budget End
2007-07-31
Support Year
1
Fiscal Year
2006
Total Cost
$205,389
Indirect Cost
Name
Louisiana State University Hsc Shreveport
Department
Biochemistry
Type
Schools of Medicine
DUNS #
095439774
City
Shreveport
State
LA
Country
United States
Zip Code
71103
Chen, Xin; Li, Yue; Feng, Meng et al. (2018) Maduramicin induces cardiac muscle cell death by the ROS-dependent PTEN/Akt-Erk1/2 signaling pathway. J Cell Physiol :
Zeng, Qingyu; Qin, Shanshan; Zhang, Hai et al. (2018) Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells. J Cell Physiol 233:516-529
Chen, Xin; Chen, Long; Jiang, Shanxiang et al. (2018) Maduramicin induces apoptosis and necrosis, and blocks autophagic flux in myocardial H9c2 cells. J Appl Toxicol 38:366-375
Zhang, Ruijie; Zhang, Nana; Zhang, Hai et al. (2017) Celastrol prevents cadmium-induced neuronal cell death by blocking reactive oxygen species-mediated mammalian target of rapamycin pathway. Br J Pharmacol 174:82-100
Barzegar, Mansoureh; Ma, Shuang; Zhang, Chao et al. (2017) SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling. Br J Cancer 117:1154-1163
Xu, Chong; Wang, Xiaoxue; Gu, Chenjian et al. (2017) Celastrol ameliorates Cd-induced neuronal apoptosis by targeting NOX2-derived ROS-dependent PP5-JNK signaling pathway. J Neurochem 141:48-62
Xu, Chong; Wang, Xiaoxue; Zhu, Yu et al. (2016) Rapamycin ameliorates cadmium-induced activation of MAPK pathway and neuronal apoptosis by preventing mitochondrial ROS inactivation of PP2A. Neuropharmacology 105:270-284
Zhou, Hongyu; Shang, Chaowei; Wang, Min et al. (2016) Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK. Biochem Pharmacol 116:39-50
Gui, Lin; Zeng, Qingyu; Xu, Zhigang et al. (2016) IL-2, IL-4, IFN-? or TNF-? enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells. Cytokine 84:37-46
Liu, Chunxiao; Ye, Yangjing; Zhou, Qian et al. (2016) Crosstalk between Ca2+ signaling and mitochondrial H2O2 is required for rotenone inhibition of mTOR signaling pathway leading to neuronal apoptosis. Oncotarget 7:7534-49

Showing the most recent 10 out of 52 publications